COMPARISONS BETWEEN THE NON-PROLIFERATIVE AND PROLIFERATIVE THERAPY IN FIBROCYSTIC MASTOSIS

Area of Science:

• Reproductive medicine and endocrinology
• Oncology
• Benign breast disease management

Background:

• Fibrocystic mastosis (FCM) is the most prevalent benign breast condition.
• Current treatments include hormonal and non-hormonal therapies with variable efficacy.
• Assessing treatment benefit-risk is crucial due to potential side effects and relapses.

Purpose of the Study:

• To evaluate the efficacy of different hormonal treatments for fibrocystic mastosis.
• To compare the outcomes of various medications in terms of symptom relief and antiproliferative effects.
• To determine the optimal approach for managing fibrocystic mastosis based on patient factors and treatment response.

Main Methods:

• A 9-month study involving 210 patients with fibrocystic mastosis, divided into 7 treatment groups.
• Data collected included patient age, mastodynia severity, breast nodule size, cyst volume, fibrous tissue reduction, and medication tolerance.
• Statistical analysis was performed to compare treatment outcomes and relapse rates.

Main Results:

• Tamoxifen and Danazol achieved a 90% reduction in mastodynia, followed by Lynestrenol and Bromocriptine (70%), and Utrogestan (50%).
• Tamoxifen demonstrated a significantly lower relapse rate compared to other treatments (p < 0.05).
• Logest, Utrogestan, and Bromocriptine primarily offered symptomatic relief (antalgic effects) without significant antiproliferative activity.

Conclusions:

• Hormonal treatments like Tamoxifen and Danazol show superior efficacy in alleviating mastodynia associated with fibrocystic mastosis.
• Histopathological examination is essential for guiding appropriate hormone therapy decisions in FCM management.
• A comprehensive assessment of drug benefits and risks, including side effects and relapse rates, is necessary for personalized treatment strategies.